Aditxt, Inc. (ADTX) Stock Analysis

Aditxt, Inc. (ADTX) Healthcare & Pipeline Overview

Aditxt, Inc. is a biotechnology company specializing in immune system monitoring and reprogramming technologies, including AditxtScore for personalized immune profiling and ADi products for organ transplantation and autoimmune diseases. The company operates within the competitive biotechnology sector, focusing on innovative approaches to immune health management.

What Is the Investment Thesis for ADTX?

Aditxt, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on immune system monitoring and reprogramming technologies, particularly AditxtScore, addresses a growing need for personalized immune health management. Key value drivers include successful commercialization of AditxtScore and the advancement of ADi products through clinical trials. Growth catalysts include potential partnerships, regulatory approvals, and positive clinical data. However, the company's negative profit margin of -362385.7% and limited market capitalization of $0.00B highlight significant financial risks. Investors should carefully consider the company's early stage of development, dependence on research and development, and the competitive landscape of the biotechnology industry.

Based on FMP financials and quantitative analysis

ADTX Key Highlights

AditxtScore is designed to provide individuals with a comprehensive understanding of their immune system.

• Apoptotic DNA Immunotherapy is a nucleic acid-based technology mimicking the body's natural process of inducing tolerance.
• The company has a license agreement with Loma Linda University and Leland Stanford Junior University.
• Aditxt's technologies target organ transplantation, skin grafting, autoimmune diseases, and allergies.
• The company reported a gross margin of 19.9%.

Who Are ADTX's Competitors?

ADTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ADTX's Key Strengths?

Innovative immune monitoring technologies.

• Strategic partnerships with universities.
• Focus on personalized medicine.
• Potential for intellectual property protection.

What Are ADTX's Weaknesses?

Limited financial resources.

• Early stage of development.
• Dependence on research and development.
• Negative profit margin.

What Could Drive ADTX Stock Higher?

Clinical trial results for ADi products in organ transplantation.

• Regulatory approvals for AditxtScore in key markets.
• Strategic partnerships with pharmaceutical companies and research institutions.
• Expansion of AditxtScore applications to new patient populations.

What Are the Key Risks for ADTX?

Financial-distress signal — its Altman Z-Score of -35.80 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Competition from established biotechnology companies.
• Regulatory hurdles and approval delays.
• Uncertainty in clinical trial outcomes.
• Limited financial resources and dependence on research and development.

What Are the Growth Opportunities for ADTX?

• Expansion of AditxtScore: Aditxt has the opportunity to expand the applications of AditxtScore beyond initial use cases. By demonstrating clinical utility in specific patient populations or disease areas, Aditxt can drive adoption by healthcare providers and patients. Timeline: Ongoing.
• Advancement of ADi Products: The development of ADi products for organ transplantation, autoimmune diseases, and allergies represents a substantial growth opportunity for Aditxt. Successful completion of clinical trials and regulatory approvals could lead to significant revenue streams. The market for therapies targeting these conditions is substantial, with a growing need for innovative solutions. Timeline: 3-5 years.
• Strategic Partnerships: Aditxt can pursue strategic partnerships with pharmaceutical companies, research institutions, and healthcare providers to accelerate the development and commercialization of its technologies. These partnerships can provide access to funding, expertise, and distribution channels. The biotechnology industry is characterized by collaborations and partnerships, making this a viable growth strategy for Aditxt. Timeline: Ongoing.
• Geographic Expansion: Aditxt can expand its geographic reach beyond the United States to tap into international markets. The demand for immune monitoring and reprogramming technologies is growing globally, presenting opportunities for Aditxt to establish a presence in key regions. This expansion could involve partnerships with local distributors or the establishment of international subsidiaries. Timeline: 2-4 years.
• Development of New Immune Monitoring Technologies: Aditxt can invest in the development of new immune monitoring technologies to complement AditxtScore and expand its product portfolio. This could involve exploring new biomarkers, developing novel assays, or integrating artificial intelligence and machine learning to enhance immune profiling capabilities. The biotechnology industry is constantly evolving, requiring companies to innovate to stay ahead of the competition. Timeline: Ongoing.

What Are ADTX's Competitive Advantages?

• Proprietary immune monitoring technologies.
• Strategic partnerships with leading research institutions.
• Focus on personalized immune health management.
• Potential for strong intellectual property protection.

What Does ADTX Do?

Aditxt, Inc., established in 2017 and formerly known as ADiTx Therapeutics, Inc. until its name change in July 2021, is a biotechnology company dedicated to enhancing immune system health through advanced immune mapping and reprogramming technologies. The company's core focus revolves around developing innovative solutions that enable individuals to better understand, manage, and monitor their immune profiles. Aditxt's flagship product, AditxtScore, is designed to provide individuals with a comprehensive understanding of their immune system, allowing them to proactively manage and monitor potential threats. In addition to AditxtScore, the company is developing Apoptotic DNA Immunotherapy, a nucleic acid-based technology that mimics the body's natural process of inducing tolerance to its own tissues. This technology is being explored for various applications, including organ transplantation, skin grafting, autoimmune diseases, and allergies. Aditxt has strategic partnerships, including a license agreement with Loma Linda University and Leland Stanford Junior University, to further its research and development efforts. Headquartered in Richmond, Virginia, Aditxt is committed to advancing the field of immune health through innovative technologies and strategic collaborations.

What Products and Services Does ADTX Offer?

• Develops AditxtScore for immune profile monitoring.
• Creates technologies for improving immune system health.
• Focuses on immune mapping and reprogramming.
• Develops ADi products for organ transplantation.
• Targets autoimmune diseases and allergies with ADi products.
• Utilizes Apoptotic DNA Immunotherapy, a nucleic acid-based technology.

How Does ADTX Make Money?

• Develops and commercializes immune monitoring products.
• Generates revenue through sales of AditxtScore and related services.
• Out-licenses technologies to partners in specific therapeutic areas.
• Pursues strategic partnerships for research and development.

What Industry Does ADTX Operate In?

Aditxt, Inc. operates within the biotechnology industry, a sector characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The market for immune monitoring and reprogramming technologies is growing, driven by increasing awareness of immune-related diseases and the demand for personalized medicine. Aditxt competes with other biotechnology companies developing similar technologies, as well as established players in the diagnostics and therapeutics markets. The company's success depends on its ability to develop and commercialize innovative products that address unmet medical needs.

Who Are ADTX's Key Customers?

• Individuals seeking to understand and manage their immune profiles.
• Healthcare providers using AditxtScore for patient monitoring.
• Pharmaceutical companies partnering with Aditxt for drug development.
• Research institutions collaborating with Aditxt on immune-related studies.

Over the past six months, Aditxt, Inc. insiders filed 24 SEC Form 4 transactions — 12 sales and 12 purchases. On net that is roughly 380K shares acquired (about $28K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Aditxt, Inc.

Revenue for Aditxt, Inc. came in at $12K during Q1 FY2026, a 2760.9% improvement versus the preceding quarter. The company recorded a net loss of $15.9M, with diluted EPS of $-790.51. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, ADTX averaged $-452.61 in diluted EPS.

Aditxt, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -35.80 places it in the distress zone, a signal of elevated financial risk.

Aditxt, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 85.4% above estimates on average.

Company Profile

Aditxt, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Mountain View, US. The company is led by CEO Jeffrey Busch. ADTX has traded publicly since 2020.

ADTX Financials

ADTX Latest News

ADTX Analyst Consensus

ADTX MoonshotScore

Latest Aditxt, Inc. Analysis

Aditxt, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources